Blog
RSS FeedPosted by Michael Wonder on 17 Aug 2020
Janssen and others have appealed NICE's decision to reject abiraterone acetate for patients with for high risk hormone-sensitive metastatic prostate cancer
17 August 2020 - The appeal panel will convene on 3 September and 4 September to hear oral representations from the ...
Posted by Michael Wonder on 13 Aug 2020
NICE recommends Adcetris for first-line use for patients with a rare form of non-Hodgkin's lymphoma
12 August 2020 - NICE has published its final guidance on the use of brentuximab vedotin in combination with chemotherapy ...
Posted by Michael Wonder on 06 Aug 2020
NICE supports use of new medicine for patients with malignant disease
5 August 2020 - Treosulphan is used as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation. ...
Posted by Michael Wonder on 05 Aug 2020
NICE publishes draft guidance on the use of a topical gel by patients with a rare cancer
5 August 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using chlormethine gel ...
Posted by Michael Wonder on 31 Jul 2020
NICE recommends Bavencio (avelumab) in combination with axitinib for first-line treatment of adult patients with advanced renal cell carcinoma
31 July 2020 - This is the first combination of an immunotherapy with a targeted antiangiogenic therapy to be recommended ...
Posted by Michael Wonder on 30 Jul 2020
NICE rejects NHS funding for Kyowa Kirin's Poteligeo
30 July 2020 - NICE is not recommending NHS funding for Kyowa Kirin's Poteligeo (mogamulizumab) as a treatment for mycosis ...
Posted by Michael Wonder on 11 Jul 2020
NICE backing for Takeda's Adcetris for rare lymphoma
10 July 2020 - Takeda's Adcetris (brentuximab vedotin) has won the backing of the National Institute for Health and Care ...
Posted by Michael Wonder on 25 Jun 2020
NICE draft guidance does not recommend siponimod for treating secondary progressive multiple sclerosis
25 June 2020 - NICE has today issued draft guidance for public consultation which does not recommend siponimod (Mayzent, Novartis) for ...
Posted by Michael Wonder on 25 Jun 2020
Cancer patients to benefit from new histology independent treatment
25 June 2020 - Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug ...
Posted by Michael Wonder on 24 Jun 2020
NICE publishes final guidance for Sobi's avatrombopag maleate
24 June 2020 - Avatrombopag maleate is used to treat patients with thrombocytopenia. ...
Posted by Michael Wonder on 17 Jun 2020
Final NICE green light for Janssen's Stelara in ulcerative colitis
17 June 2020 - NICE has now issued a final green light for NHS use of Janssen's Stelara (ustekinumab) to ...
Posted by Michael Wonder on 15 Jun 2020
NICE backs Rozlytrek for subset of NSCLC patients
15 June 2020 - NICE has published final draft guidance backing NHS use of Roche's Rozlytrek (entrectinib) as a treatment ...
Posted by Michael Wonder on 12 Jun 2020
NICE rejects Sanofi's Cablivi in draft guidelines
12 June 2020 - NICE has drawn up draft guidelines rejecting Sanofi's Cablivi (caplacizumab) for use alongside plasma exchange and immunosuppression ...
Posted by Michael Wonder on 11 Jun 2020
Tafamidis for treating transthyretin amyloid cardiomyopathy
11 June 2020 - The Department of Health and Social Care has asked the NICE to produce guidance on using tafamidis ...
Posted by Michael Wonder on 10 Jun 2020
Final NHS green light for Roche's Kadcyla
10 June 2020 - NICE has published final guidance backing NHS use of Roche's Kadcyla (trastuzumab emtansine) for the adjuvant ...